Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 HKD | -3.08% | -6.67% | -13.70% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.18B 163M 1.28B |
---|---|---|---|---|---|
Net income 2024 * | -219M -30.24M -236M | Net income 2025 * | -242M -33.42M -261M | EV / Sales 2024 * | - |
Net cash position 2024 * | 2B 276M 2.16B | Net cash position 2025 * | 1.7B 234M 1.83B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.76
x | P/E ratio 2025 * |
-5.14
x | Employees | 219 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.46% |
1 day | -3.08% | ||
1 week | -6.67% | ||
Current month | -3.08% | ||
1 month | -7.35% | ||
3 months | -30.77% | ||
6 months | -34.72% | ||
Current year | -13.70% |
Managers | Title | Age | Since |
---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Yan Yuemei
CTO | Chief Tech/Sci/R&D Officer | - | - |
Handan He
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Jiong Gu
BRD | Director/Board Member | 51 | 18-03-31 |
Chief Operating Officer | 50 | 19-03-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.78% | 4 M€ | -27.92% | ||
0.00% | 34 M€ | +4.20% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 1.26 | -3.08% | 1,598,000 |
24-05-23 | 1.3 | -2.26% | 867,000 |
24-05-22 | 1.33 | -1.48% | 810,000 |
24-05-21 | 1.35 | -2.17% | 691,000 |
24-05-20 | 1.38 | +2.22% | 3,105,000 |
Delayed Quote Hong Kong S.E., May 24, 2024 at 04:08 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.70% | 163M | |
-2.00% | 90.02B | |
-1.18% | 39.15B | |
-15.83% | 31.71B | |
+62.86% | 26.47B | |
-21.68% | 14.34B | |
-8.73% | 12.89B | |
-15.05% | 11.18B | |
-45.69% | 10.97B | |
+4.94% | 8.94B |
- Stock Market
- Equities
- 1672 Stock